Life science is one of the industries most affected by the constant pressure put on supply chains. As a highly regulated industry, it is answerable to mandates and evolving customer needs, but must have the flexibility to create innovative solutions in pharmaceuticals, medical devices, health tech, and more. This leaves it vulnerable to changes in supply demand and supply access. Having a plan for overcoming the challenges is essential.
Since the pandemic, some life sciences groups have been able to diversify their vendors, but due to regulations this can’t resolve every need. If a life sciences product is regulated or has been specifically tested through clinical trials, a change could completely alter the impact or open the organization up to additional risk.
Read the full article at: www.lifescienceleader.com
